Research & Development

Breast cancer treatments must adapt for elderly patients

Breast cancer_ribbonThe report* shows that despite many pharmacological treatment options being available for breast cancer treatment, including chemotherapy, hormonal therapy and targeted therapy, patients still fear relapses or resistant tumours.

Barriers to overcome in lupus drug development



There are four main types of lupus: neonatal, discoid (DLE), drug-induced (DIL) and systemic lupus erythmatosus (SLE). When lupus is discussed, most often times it is in reference to SLE as it affects the majority of patients.

Lupus is a chronic autoimmune disease that presents in masquerading ways thus making for difficult and precise diagnosis. 

Need for breakthrough renal disease treatments

Need-for-breakthrough-renal-disease-treatmentsThe rising incidence of kidney disease due to increasing obesity, high blood pressure and diabetes is forming a gigantic market for new renal disease treatments, according to a new report by GlobalData.

European Medicines Agency recommends limiting long-term use of calcitonin medicines

CalcitoninThe European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that calcitonin-containing medicines should only be used for short-term treatment, because of evidence that long-term use of these medicines is associated with an increased risk of cancer.

MEK inhibitors: A new weapon in fighting melanoma

MEK-inhibitors-A-new-weapon-in-fighting-melanomaCancer cell signalling has long been an attractive target for oncology drug development. Increased activation of cell survival signalling cascades promotes tumour cell growth and makes cancer cells difficult to kill. Inhibiting proteins that are involved in these survival pathways is one strategy to selectively destroy cancerous cells. The mitogen activated protein kinase (MAPK) pathway is one such signalling cascade that, when activated, promotes cell survival. Preclinical research has found that this pathway is activated in most melanomas; consequently, one of the key kinases involved in this pathway, MEK, has become the focus of targeted therapies for the treatment of melanoma. MEK, which stands for MAPK/ ERK kinase and is also known as MAPKK, has several known structural variants called ‘isoforms’ which play different roles within the cell. Isoforms 1 and 2, referred to as MEK1/2, are the isoforms associated with MEK’s ability to promote cell survival.

Would you like to receive our FREE e-newsletter?

* indicates required